HIV
Conditions
Keywords
HIV infection, Early treatment, Romidepsin, HDACi, Therapeutic Vaccines, HIVconsv, HIV reservoir, Population PK/PD analysis
Brief summary
The BCN02-Romi study aims to evaluate a combined kick and kill strategy using the most immunogenic candidate vaccine available so far (HIVconsv) with the strongest latency reversal agent available at present time (romidepsin) in a cohort of early-treated HIV positive individuals.
Detailed description
The combined use of therapeutic vaccination and specific drugs that can reactivate latent virus from the reservoir (Kick and kill strategies) hold the promise to achieve functional cure and viral eradication of HIV infection. The present project consists of a proof-of-concept clinical trial in a cohort of 24 early treated HIV-1 infected individuals rolled-over from the BCN01 vaccine clinical trial in which participants received the most immunogenic vaccines tested to date, ChAd and modified vaccinia Ankara (MVA).HIVconsv vaccines. All individuals will be given a booster immunization with MVA.HIVconsv in combination with romidepsin (RMD), a potent histone deacetylation inhibitor (HDACi) and will later undergo a monitored antiretroviral pause. HIVconsv vaccines have specifically been designed to stimulate a broad and potent cytotoxic T cell (CTL) response towards the most conserved viral regions of the HIV-1 proteome, which have recently been suggested to have a crucial role when targeting HIV variants harboured in the latent reservoir with mutations to escape T-cell immune responses. The study includes the development of a population pharmacokinetic/pharmacodynamic (PK/PD) substudy to analyse the in vivo effects of RMD in the induction of HIV expression in resting cells, deeply investigate any unintended effect on the CTL function as well as predict the relationship between RMD exposure and such effects. The investigators' results will allow investigators to optimize RMD dosing, to evaluate the clinical efficacy of this eradication strategy after the cART interruption and to identify better correlates of control of rebound viremia after cessation of treatment.
Interventions
DRUGMVA.HIVconsv vaccine
Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
DRUGRomidepsin
Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
Sponsors
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Hospital Clinic of Barcelona
Hospital de Sant Pau
HIVACAT
University of Oxford
BCN Checkpoint
IrsiCaixa
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Subject included in ChAd-MVA.HIVconsv\_BCN01 study with complete follow-up and included in BCN01-RO extension study. 2. Optimal virological suppression for at least 3 years.cop/ml). 3. Being on a non-boosted integrase-inhibitor based regimen (raltegravir or dolutegravir) for at least 4 weeks at screening visit. 4. Haematological and biochemical laboratory parameters as follows: * Haemoglobin \> 10g/dl * Platelets \> 100.000/dl * Alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) * Creatinine ≤ 1.3 x ULN 5. CD4 T cell count ≥500 cells/mm3
Exclusion criteria
1. Positive pregnancy test. 2. Presence of resistance drug mutations in the screening genotype 3. History of autoimmune disease other than HIV-related auto-immune disease. 4. Treatment for cancer or lymphoproliferative disease within 1 year of study entry 5. Any other prior therapy which, in the opinion of the investigators, would make the individual unsuitable for the study or influence the results of the study 6. Current or recent use (within last 3 months) of interferon or systemic corticosteroids or other immunosuppressive agents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with grade >=3 adverse events assessed by Division of AIDS (DAIDS) grading table | Through study completion, maximum 75 weeks | Grade \>=3 adverse events |
| Number of participants with serious adverse events | Through study completion, maximum 75 weeks | Serious adverse events |
| Viral reservoir measured by total HIV-1 DNA copies per 10e6 CD4+ T cells | From baseline to visit week 6 (romidepsin 3 + 1 week) | Total HIV-1 DNA copies per 10e6 CD4+ T cells |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Romidepsin AUC | week 4 | RMD plasma concentrations will be measured by LC-MS/MS |
| HIV-1 expression in resting CD4+ T-cells measured by CA-RNA and single-copy assay (SCA) | week 6 | — |
| Levels of Histone H3 acetylation in lymphocytes | week 6 | — |
| CTL toxicity assessment based on viability, activation or exhaustion (most relevant marker according to previous studies) | week 6 | — |
| HIVconsv-specific T cell responses will be measured by IFNg ELISPOT using peptide pools covering different HIV proteins and HIVcons sequences. | week 6 | — |
| Romidepsin Cmax | week 3 | RMD plasma concentrations will be measured by Liquid chromatography-mass spectrometry (LC-MS/MS) |
| Proportion of individuals who initiate a MAP following the futility analysis | Week 17 | — |
| Proportion of individuals who maintain sustained plasma viral load (pVL) <2,000 copies/ml | Week 29 | — |
| Proportion of individuals in whom cART is reinitiated due to viral rebound | Up to 51 weeks | — |
| Emergence of viral resistance during MAP phase | Up to 51 weeks | Description of viral resistance emerged, genotype. |
| Proportion of patients with viral suppression 6 months after treatment resumption. | 24 weeks after treatment resumption (up to 75 weeks). | — |
| Viral suppressive capacity of CD8+ T cells in vitro, using a flow cytometric assay | Baseline | — |
| Romidepsin Cmin | week 3 | RMD plasma concentrations will be measured by LC-MS/MS |
| Romidepsin area under curve (AUC) | week 3 | RMD plasma concentrations will be measured by LC-MS/MS |
Countries
Spain
Outcome results
None listed